Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic edoxaban 60 mg versus Lixiana 60 mg in healthy Thai volunteers under fasting conditions
TCTR20260920004Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edoxaban (2 arms), sponsored by International Bio Service. Primary endpoints: Cmax, AUC0-tlast and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
edoxaban
Beyond the preview
Go deeper on TCTR20260920004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260920004.